ATARA BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | Aug 2025 | Jun 2025 | May 2025 | Mar 2025 | Feb 2025 | Dec 2024 | Nov 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $17.6M | — | $98.1M | — | — | — | $40.2M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $7.3M | — | $27.4M | — | — | — | $43.9M |
| SG&A Expense | — | $6.5M | — | $11.5M | — | — | — | $10.4M |
| Operating Income | — | $3.2M | — | $38.8M | — | — | — | $-21.8M |
| Operating Margin | — | 18.2% | — | 39.5% | — | — | — | -54.1% |
| Interest Expense | — | $972.0K | — | $1.0M | — | — | — | $1.2M |
| Pretax Income | — | $2.4M | — | $38.0M | — | — | — | $-21.9M |
| Income Tax Expense | — | $3.0K | — | $0 | — | — | — | $-17.0K |
| Net Income | — | $2.4M | — | $38.0M | — | — | — | $-21.9M |
| Net Margin | — | 13.6% | — | 38.7% | — | — | — | -54.5% |
| EPS (Basic) | — | $0.20 | — | $3.53 | — | — | — | $-2.93 |
| EPS (Diluted) | — | $0.19 | — | $3.50 | — | — | — | $-2.93 |
| Shares Outstanding (Basic) | 7.0M | 12.2M | 6.0M | 10.8M | 5.9M | 5.9M | 5.8M | 7.5M |
| Shares Outstanding (Diluted) | 7.0M | 12.3M | 6.0M | 10.9M | 5.9M | 5.9M | 5.8M | 7.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |